SSI Strategy Acquired by Clinigen Group

6749 SSI Strategy NT

M&A Engagement Overview

Industry Group: Healthcare & Life Sciences
Area of Focus: Outsourced Pharma Services

Harris Williams advised SSI Strategy, a portfolio company of Amulet Capital Partners, on their sale to Clinigen Group, a portfolio company of Triton Partners. SSI provides a fully integrated offering to address medical, clinical, regulatory, safety, and organizational challenges at all stages of drug development. The company delivers the strategic insight, technical expertise, and collaborative support biotech leaders need to bring lifesaving therapies to patients.

Outsourced pharma services continue to be a highly sought after sector for investors. As drug development becomes more complex, specialized, and capital-intensive, pharma and biotech organizations are increasingly relying on innovative external partners to manage critical functions.

SSI serves a diverse and growing biotech client base from early development through launch across a comprehensive range of scientific functions, including clinical development and operations, strategic program management, regulatory strategy, medical affairs, safety, and evidence and value.

As a go-to strategic partner for biotech leaders, SSI embeds seasoned executives and operators directly into organizations to accelerate progress and reduce risk. From concept to commercialization, the company works as an extension of internal teams to empower employees, enhance performance, and accelerate progress.  

The combination of the two companies incorporates SSI’s strategic depth, established U.S. and European footprint, and pioneering partnership models with Clinigen’s global operational reach and experience in clinical trial supply, managed access, and commercialization – creating a comprehensive global partner for the biopharma industry from early-stage strategy to commercialization.

Contact the Harris Williams Healthcare & Life Sciences Group to learn more about this client engagement.

Harris Williams is a global investment bank specializing in M&A and private capital advisory services. Clients worldwide rely on us to help unlock value in their business and turn ambitious goals into reality. We approach every engagement with boundless collaboration, pooling expertise and relationships across industries and geographies. For over 30 years, our clients have trusted us to think strategically, execute precisely, and deliver superior outcomes to help them grow.


Harris Williams LLC is a registered broker-dealer and member of FINRA and SIPC. Harris Williams & Co. Ltd is a private limited company incorporated under English law with its registered office at 13th floor, One Angel Court, London EC2R 7HJ, UK, registered with the Registrar of Companies for England and Wales (registration number 07078852). Harris Williams & Co. Ltd is authorised and regulated by the Financial Conduct Authority, number 5408952. Harris Williams Private Capital Advisory Ltd. is an Appointed Representative of Sturgeon Ventures, LLP, which is authorised and regulated by the Financial Conduct Authority number 452811. Harris Williams & Co. Corporate Finance Advisors GmbH is registered in the commercial register of the local court of Frankfurt am Main, Germany, under HRB 107540. The registered address is 16th Floor, Marienturm, Taunusanlage 9-10 60329, Frankfurt am Main, Germany (email address: hwgermany@harriswilliams.com). Geschäftsführer/Director: Paul Poggi, VAT No. DE321666994. Harris Williams is a trade name under which Harris Williams LLC, Harris Williams & Co. Ltd and Harris Williams & Co. Corporate Finance Advisors GmbH conduct business.